Summary
Rare disease trials differ from those in most other therapeutic areas because the indications are more complex and involve smaller patient populations. It is essential to understand the current disease landscape, the prior research, and the competitive clinical trial environment when posi¬tioning a new clinical trial within the rare disease space. This white paper discusses strategies for accelerating rare disease clinical development by lever¬aging data in a more evidence-based approach to guide the design of a trial; to understand treat¬ment trends; and to identify the best investigators, sites, and patients.
Register to download
Strategies for Accelerating Rare Disease Clinical Development
You may also be interested in:
page
Medical Director
At PRA, Medical Directors have the unique opportunity to impact a broad patient population while staying focused on their therapeutic area of…
Case Study
Achieving Challenging Recruitment Goals and Timelines in a Pediatric Type 2 Diabetes Study
Recruiting pediatric patients for type 2 diabetes mellitus (T2DM) studies is extremely challenging. Patients are difficult to identify and often face…
Fact Sheet
Central Review Services
PRA's Central Review Services team, unique in the CRO industry, offers lupus-specific expertise in efficacy endpoint data correlation, standardized…